Skip to main content
. 2022 Nov 24;14(12):2590. doi: 10.3390/pharmaceutics14122590

Figure 1.

Figure 1

Lifespan of G93A mice treated with intranasal administration of NAC/PEG-PCL-Tat. G93A mice were treated with NAC-IP (1 mg), NAC-IN (1 mg), PEG-PCL-Tat (IN), 0.2NAC/PEG-PCL-Tat (IN; 0.2 mg), or NAC/PEG-PCL-Tat (IN; 1 mg), starting at a late symptomatic stage (15 weeks old). (A) Survival curves were analyzed using Kaplan–Meier survival analysis with the log-rank test; (B) The graph shows the lifespan comparative result. The values are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test. * p < 0.05, ** p < 0.01, and *** p < 0.001.